Ondansetron in the treatment of cognitive decline in Alzheimer dementia

Maurice Dysken, Michael Kuskowski, Susan Love, Nathan Billig, Richard Borison, Rachelle Doody, David Drachman, Eugene DeBoff, David Dunner, Mildred Farmer, Sanford Finkel, Norman Foster, Arthur Freeman, Neill Graff-Radford, Robert Green, George Grossberg, Hugh Hendrie, William Jagust, Lawrence Jenkyn, John MorrisSheldon Preskorn, Mary Sano, Benjamin Seltzer, Paul Tuttle

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 μg/day and 100 μg/day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.

Original languageEnglish
Pages (from-to)212-215
Number of pages4
JournalAmerican Journal of Geriatric Psychiatry
Volume10
Issue number2
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint Dive into the research topics of 'Ondansetron in the treatment of cognitive decline in Alzheimer dementia'. Together they form a unique fingerprint.

  • Cite this

    Dysken, M., Kuskowski, M., Love, S., Billig, N., Borison, R., Doody, R., Drachman, D., DeBoff, E., Dunner, D., Farmer, M., Finkel, S., Foster, N., Freeman, A., Graff-Radford, N., Green, R., Grossberg, G., Hendrie, H., Jagust, W., Jenkyn, L., ... Tuttle, P. (2002). Ondansetron in the treatment of cognitive decline in Alzheimer dementia. American Journal of Geriatric Psychiatry, 10(2), 212-215. https://doi.org/10.1097/00019442-200203000-00013